Skip to main content

Table 2 Baseline cardiovascular characteristics for all patients

From: Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis

  RA
(n = 64)
PsA
(n = 29)
AS
(n = 20)
MTX
(n = 49)
anti-TNF ± MTX
(n = 6)
Cardiovascular risk factors
 Hypertension 17 (27) 7 (24) 6 (30) 9 (18) 21 (33)
 BMI (kg/m2), median (range) 26 (19–41) 26 (19–39) 28 (22–36) 26 (20–39) 27 (20 – 41)
 Hyperlipidemia 11 (17) 3 (10) 3 (15) 9 (18) 8 (12)
 Current smokers 20 (31) 6 (21) 10 (50) 15 (31) 21 (33)
 Family history of CVD or death 33 (52) 13 (45) 10 (50) 24(50) 32 (50)
 Diabetes 3 (5) 0 (0) 1 (5) 0 (0) 4 (6)
Medical history
 Previous myocardial infarction 5 (8) 0 (0) 2 (10) 2 (4) 5 (8)
 Angina pectoris 2 (3) 1 (3) 2 (10) 2 (4) 3 (5)
Endothelial dysfunction
 RHI, median (range) 1.89 (1.24–2.94) 2.06 (1.45–2.94) 1.81 (1.37–2.72) 1.93 (1.24–2.76) 1.82 (1.37–2.94)
 ED 22 (34) 9 (31) 9 (45) 18 (37) 22 (34)
 RHI, median (range) for patients with ED 1.47 (1.24–1.65) 1.56 (1.45–1.64) 1.52 (1.37–1.64) 1.49 (1.24–1.63) 1.52 (1.37–1.65)
  1. Unless indicated otherwise, values are given as number (percentage)
  2. Statistically significant differences are shown in bold typeface
  3. P < 0.05, versus PsA
  4. anti-TNF antitumor necrosis factor, AS ankylosing spondylitis, BMI body mass index, CVD cardiovascular disease, ED endothelial dysfunction, MTX methotrexate, PsA psoriatic arthritis, RA rheumatoid arthritis, RHI Reactive Hyperemic Index